

**ASX Announcement | 26 October 2020
Vioneering Technologies (ASX:VTI)**

Sale of Shares by CEO and Executive Director

Atlanta, Georgia, USA, 25 October 2020 (26 October 2020 Australia): As disclosed in the attached Appendix 3Y, Stephen Snowdy, CEO and Executive Director of Vioneering Technologies, Inc (ASX:VTI) (**Company**) has sold 1,000,000 VTI Class A Common Stock. This sale of stock was to cover tax obligations related to restricted shares awarded in lieu of cash compensation in FY2020. Dr. Snowdy continues to hold 55,828,800 securities in VTI, composed of 11,172,829 Class A common stock, 1,934,068 restricted shares of Class A Common Stock, and 42,721,903 Options.

Ends

This release was authorized by the CEO, Stephen Snowdy, PhD.

For more information, please contact:

Vioneering Technologies

Stephen Snowdy, PhD

CEO & Executive Director

E: ssnowdy@vtivision.com

Investor & Media Relations

Julia Maguire

The Capital Network

M: +61 02 8999 3699

E: julia@thecapitalnetwork.com.au

NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens Indication for Use Outside the United States: NaturalVue (etafilcon A) Multifocal Daily Disposable Soft (Hydrophilic) Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) and/or presbyopia, and myopia progression control in aphakic and/or non-aphakic persons with non-diseased eyes in powers from -20.00 to +20.00 dioptres and with non-diseased eyes who may require a reading addition of up to +3.00D. The lenses may be worn by persons who exhibit astigmatism of 2.00 dioptres or less that does not interfere with visual acuity.

About Vioneering Technologies

Vioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Vioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Vioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

Foreign Ownership Restrictions

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Visioneering Technologies, Inc
ARBN	616 156 248

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Stephen Snowdy
Date of last notice	05 October 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
Date of change	1. 21 October 2020 2. 26 October 2020
No. of securities held prior to change	11,786,016 shares of Class A common Stock 2,320,881 restricted shares of Class A Common Stock 39,343,182 options with an exercise price of US\$0.0118 per share of Class A Common Stock with an expiry date of 01 June 2030 3,378,721 options with an exercise price of US\$0.0185 per share of Class A Common Stock with an expiry date of 01 June 2030
Class	Restricted shares of Class A Common Stock and Class A Common Stock

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number acquired	386,813 Class A Common Stock
Number disposed	386,813 Restricted shares of Class A Common Stock 1,000,000 Class A Common Stock
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. \$0.048 2. \$Nil
No. of securities held after change	11,172,829 shares of Class A Common Stock 1,934,068 restricted shares of Class A Common Stock 39,343,182 options with an exercise price of US\$0.0118 per share of Class A Common Stock with an expiry date of 01 June 2030 3,378,721 options with an exercise price of US\$0.0185 per share of Class A Common Stock with an expiry date of 01 June 2030
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1. On-market trade. 2. Partial vesting of Restricted Shares of Class A Common Stock.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Date of Notice: 26 October 2020

+ See chapter 19 for defined terms.